Flamingo Therapeutics to Present Poster on FLM-7523 at EACR 2024 Congress

LEUVEN, Belgium and STRASBOURG, France – Flamingo Therapeutics has disclosed a key presentation on its innovative therapy candidate FLM-7523, also known as FTX-001, during the Annual Congress of the European Association for Cancer Research (EACR) 2024. This conference is taking place in Rotterdam, Netherlands, from June 10-13, 2024.

FLM-7523 is a novel oligonucleotide designed to target the long non-coding RNA MALAT1, which is implicated in cancer progression. Flamingo’s presentation will focus on the preclinical results that have underlined the candidate selection and characterization of FLM-7523. These promising findings have propelled FLM-7523 through Phase 1 enabling preclinical activities, and the company is now preparing for a First-in-Human trial aimed at treating solid tumors.

Details of the EACR poster are as follows:
- Abstract Number: EACR2024-0240
- Title: "Preclinical development of FTX-001: First-in-class inhibitor of the long non-coding RNA MALAT1"
- Session Title: Posters: Experimental/Molecular Therapeutics, Pharmacogenomics
- Session Date and Time: June 11, 2024, from 11:00 to 20:15
- Presenting Author: Dr. Marie-Aline Neveu

The abstracts related to the EACR meeting will be available online in a supplement to the FEBS journal, Molecular Oncology, as well as on the Congress App and the Congress Website.

Flamingo Therapeutics is at the forefront of developing RNA-targeted therapies for oncology, with a robust clinical-stage pipeline aimed at undruggable transcription factors and long non-coding RNAs. The company has established a strategic alliance with Ionis Pharmaceuticals and receives backing from notable biotechnology investors including Abrdn, Andera Partners, Bpifrance Large Venture, Eurazeo - Kurma Partners, Perceptive Advisors, PMV, Pontifax, Sphera, and VIB.

In addition to its work on FLM-7523, Flamingo has initiated several clinical trials. A notable Phase II trial named 'PEMDA-HN' is currently ongoing, which evaluates the combination of the STAT3 targeting agent danvatirsen with pembrolizumab in patients suffering from head and neck squamous cell carcinoma (HNSCC). Furthermore, a Phase I investigator-initiated trial is investigating the efficacy of danvatirsen as a monotherapy and in combination with venetoclax in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

These initiatives highlight Flamingo’s commitment to advancing the field of oncology through innovative RNA-targeted therapies, aiming to provide new treatment avenues for patients with challenging cancers.

In summary, Flamingo Therapeutics is making significant strides in cancer treatment research with its pioneering work on FLM-7523 and other promising therapeutic agents. The upcoming presentation at the EACR 2024 Congress represents an important milestone in the development of their RNA-targeted therapies, potentially offering new hope for patients battling various forms of cancer.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!